Oxybutynin Articles
Overactive bladder gel gets FDA nod
9 December 2011
Watson presents data on Ph III urology products
2 June 2008
First launch for UCB's Kentera for OAB
25 April 2005
Watson Pharma's EPS tops analysts' hopes
21 February 2005
Watson's Oxytrol OKed in Canada
5 July 2004
Watson's oxybutynin patch gets EU OK
28 June 2004
Paladin signs licensing accord with Watson
19 January 2004
Watson licenses novel product to UCB
6 October 2003
Oxytrol accepted for review in Canada
2 June 2003
Watson signs sales force deal with Ventiv
24 March 2003
Watson's incontinence patch cleared by US FDA
3 March 2003
Watson gets US OK on new use for Alora
15 April 2002
Watson sees 2001 revenues, income rise
25 February 2002
Positive results for Watson's Oxytrol
16 August 2001
Watson files NDA for oxybutynin patch
1 May 2001
Japanese Collaboration To Market Oxybutynin Patch
16 October 1997
Showing 1-18 of 18 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
